MDN Pharmaceutics

Active

Private limited companyfounded 2025incorporated this yearIeperlaan 34, 1000 Brussel, BelgiumKBO/BCE: BE 1032.175.218

MDN Pharmaceutics is younger than twelve months; there is no public track record yet to compute a bankruptcy probability from. The annual accounts of MDN Pharmaceutics for fiscal year 2025 show a net loss of 56% of total assets. The 2025 annual accounts show equity of €873 and a net result of €-1k. Its solvency ranks better than 57% of 10253 sector peers (fiscal year 2025). The company has been active since 2025 and the Belgian State Gazette contains no insolvency or warning signals.

Watch Print / PDF

Checked score

Score 2025

43 / 100

Weak

The score weighs solvency, liquidity and profitability. Every signal that weighs is under Signals.

Axes

Profitability0

Solvency69

Growth-

Track record50

Credit verdict

No publishable credit limit; credit only on tighter terms

Net loss of at least half of total assets or of the equity at the start of the financial year.

balance sheet total too small for a liquidity verdict.

How do we compute this score?

Credit advice for your own amount and term

Signals

Three signals. The signal on the left, the evidence on the right.

+raises risk○neutral

Young company

Founded in 2025, under 3 years, statistically higher risk.

KBO · incorporation date

Age against the risk zone

Filed after the deadline

The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 10-08-2026, 10 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.

NBB · 1 filing

Deviation from the deadline

2025

10 d late

← before the deadline after the deadline →

No strike-offs in the KBO publications

We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.

KBO publications · our coverage

Financials · fiscal year 2025, abbreviated schema

Equity

€873

Total assets

€2k

Net result

€-1k

Working capital

€873

Turnover and EBIT margin not published: the abbreviated schema does not require them.

Balance-sheet composition

Equity and liabilities €2k

43.7%

56.3%

Equity €873

Debt €1k

Debt finances 56.3% of the balance-sheet total.

Key figures and ratios

2025 value

Debt

€1k

Debt ≤ 1 year

€1k

Ratios withheld: a balance sheet total of €2k is too small for a meaningful ratio.

Filed annual accounts

As filed with the NBB · 2025

Balance sheet Code2025

Assets

Total assets20/58€2k

Current assets29/58€2k

Amounts receivable within one year40/41€1k

Trade receivables40€1k

Cash at bank and in hand54/58€647

Equity and liabilities

Total equity and liabilities10/49€2k

Equity10/15€873

Contributions10/11€2k

Profit (loss) carried forward14€-1k

Amounts payable17/49€1k

Amounts payable within one year42/48€1k

Trade debts44€1k

Suppliers440/4€1k

Income statement Code2025

Gross operating margin9900€-1k

Operating profit (loss)9901€-1k

Profit (loss) for the period before taxes9903€-1k

Profit (loss) for the period9904€-1k

Profit (loss) for the period to be appropriated9905€-1k

Appropriation of the result

Profit (loss) to be appropriated9906€-1k

The notes to these accounts (1 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Download as CSV

Timeline · acts, filings and financial milestones

All 1Filings 1

2026

10-08

NBB filing Annual accounts filed

fiscal year 2025 · abbreviated schema · 10 days late

NBB filing

Directors · office · real estate

Directors

1 act for this company is in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.

Location & real-estate footprint

Registered office, Brussel · 1 establishment unit since 2025

establishment The establishment unit on the map

Cannot be placed on the map

This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.

Ieperlaan 341000 Brussel

Ground area

455 m²

Building footprint

410 m²

Volume, LiDAR

8,967 m³

Parcel 21812N1454/00F009, Brussels · tallest building 29.1 m, ±7 floors. Linked by address, not a title deed.

1 establishment unit

MDN Pharmaceutics

Ieperlaan 34, 1000 BrusselRetail sale of pharmaceutical products

since 20252.385.355.407

1 parcel

Brussels 1 (100%)

Parcel (capakey)	Region	Area	Buildings	Height / fl.
21812N1454/00F009	Brussels	455 m²	1 · 410 m²	29.1 m · 7 fl.

Linked by address, not proof of ownership

Methodology

via registered seat: 1

1 of 1 parcel with an exact address match; the rest are indicative.

Linked through address data, this is not proof of ownership.

Similar companies · same sector, comparable size

Sint-Jans-Molenbeek · Eq €999

APOTHEEK VERSCHAEVE-BARTELEN

BE 0451.903.303

Beveren-Kruibeke-Zwijndrecht · Eq €1k

LISANNE MOONS

BE 0737.837.230

Zonhoven · Eq €1k

Of 5,224 companies in sector 47730 we hold annual accounts for 3,864. 76 are within a factor 10 of this equity.See the whole sector

Company data · Crossroads Bank

Identification

Legal formPrivate limited company

Founded24-12-2025

Fiscal year end31-12

Activities, NACEBEL

47730Retail sale of pharmaceutical products

47741Retail sale of medical and orthopaedic goods, excluding prescription glasses and lenses

47920Retail trade

70200Business and other management consultancy

86970Human health activities

Sources

Crossroads Bank for EnterprisesNational Bank · 1 filingAddress and cadastre registers

Data from official sources, last processed on 16-09-2026. Scores and ratios are computed by Checked and are not a credit decision.